Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor is a potent transcription factor that plays a key role in the regulation of cellular responses to stress. It is controlled by its negative regulator MDM2, which binds directly to p53 and inhibits its transcriptional activity. MDM2 also targets p53 for degradation by the proteasome. Many tumors produce high levels of MDM2, thereby impairing p53 function. Restoration of p53 activity by inhibiting the p53-MDM2 interaction may represent a novel approach to cancer treatment. RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2. In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“By binding to MDM2, RG-7112 inhibits the interaction between p53 and MDM2, preventing the degradation of the p53 proteasome, which leads to stabilization and increased levels of the tumor suppressor protein p53 in the cell.369”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [369]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“MDM4 amplification was even shown to reduce sensitivity of cells to Nutlin-3 [29–31].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“WB138 increases the levels of both p53 and MDM2, which is consistent with the activity of previous reports on MDM2 inhibitors[28,32–36].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [35]
In the citing paper
“RG7112 was modified by Roche based on the structure of Nutlins and was the first to be introduced into clinical trials (Fig. 4) [19].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [19]
In the citing paper
“The crystal structure showed that the 4-chlorophenyl ring occupied the Trp23 and Leu26 pockets, while the ethoxy group was prominently located in the Phe19 pocket341 (Fig. 8d).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [341]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Self-citation
Research works printed but not linked: 2
- Iwakuma T., 2003, Mol. Cancer Res., 1, 993
- Vu B. T., 2011, Curr. Top. Microbiol. Immunol., 348, 151
Cited by
Items 101–200 of 453
Moreira, J., Almeida, J., Saraiva, L., Cidade, H. M., & Pinto, M. M. M. (2021) · Molecules · doi:10.3390/molecules26123737 · Cited by 54
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Recent Advances in Cancer Therapeutics
Chessum, N. E. A., Jones, K., Pasqua, E., & Tucker, M. (2015) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2014.11.002 · Cited by 53
Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Roth, H. S., & Hergenrother, P. J. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666151127201829 · Cited by 51
Computational and Artificial Intelligence Techniques for Drug Discovery and Administration
Balasubramanian, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00015-3 · Cited by 50
Zhang, S., Lou, J., Li, Y., Zhou, F., Yan, Z., Lyu, X., & Zhao, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00940 · Cited by 43
Rew, Y., Sun, D., Yan, X., Beck, H. P., Canon, J., Chen, A., Duquette, J., Eksterowicz, J., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501550p · Cited by 45
A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
Skalniak, L., Surmiak, E., & Holak, T. A. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1582645 · Cited by 43
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma
Woodfield, S. E., Shi, Y. P., Patel, R. H., Chen, Z., Shah, A. P., Srivastava, R. K., Whitlock, R. S., Ibarra, A. M., Larson, S. R., Sarabia, S. F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82542-4 · Cited by 47
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives
Bouligny, I. M., Maher, K. R., & Grant, S. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100996 · Cited by 47
Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L. (2019) · Cancers · doi:10.3390/cancers11071014 · Cited by 46
“Following the initial discovery of nulin-3a in 2004, the more potent representative of this family, RG7112, was developed [114].”
BackgroundThe Role of MDM2 in Promoting Genome Stability versus Instability
Saadatzadeh, M., Elmi, A., Pandya, P., Bijangi-Vishehsaraei, K., Ding, J., Stamatkin, C., Cohen-Gadol, A., & Pollok, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102216 · Cited by 41
Choi, J., Bogenberger, J. M., & Tibes, R. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00711-3 · Cited by 46
Wang, Y., Liu, X., Huang, W., Liang, J., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108303 · Cited by 46
Zanjirband, M., Curtin, N., Edmondson, R. J., & Lunec, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19266 · Cited by 44
A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer
Miller, J. J., Gaiddon, C., & Storr, T. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00163e · Cited by 42
Chemical Variations on the p53 Reactivation Theme
Ribeiro, C. J. A., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2016) · Pharmaceuticals · doi:10.3390/ph9020025 · Cited by 42
The Ubiquitin System: An Emerging Therapeutic Target for Lung Cancer
Jin, J., Puranik, N., Bui, Q. T., Yadav, D., & Lee, P. C.-W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179629 · Cited by 42
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40
Tetra-substituted imidazoles as a new class of inhibitors of the p53–MDM2 interaction
Vaupel, A., Bold, G., Pover, A. D., Stachyra, T., Lisztwan, J. H., Kallen, J. A., Masuya, K., & Furet, P. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.039 · Cited by 40
Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions
Mousson, A., Sick, É., Carl, P., Dujardin, D., Mey, J. D., & Rondé, P. (2018) · Cancers · doi:10.3390/cancers10090278 · Cited by 41
Li, W., Peng, X., Lang, J., & Xu, C. S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00631 · Cited by 39
Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy
McPherson, K. S., & Korzhnev, D. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00101a · Cited by 39
p53 and Myofibroblast Apoptosis in Organ Fibrosis
McElhinney, K., Irnaten, M., & O'Brien, C. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076737 · Cited by 39
Spirooxadiazoline oxindoles with promising in vitro antitumor activities
Ribeiro, C. J. A., Amaral, J. D., Rodrigues, C. M. P., Moreira, R., & Santos, M. M. M. (2015) · MedChemComm · doi:10.1039/c5md00450k · Cited by 38
Allosteric Modulators of Protein–Protein Interactions (PPIs)
Ni, D., Liu, N., & Sheng, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_13 · Cited by 38
Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells
Sachweh, M. C. C., Stafford, W. C., Drummond, C. J., McCarthy, A. R., Higgins, M., Campbell, J., Brodin, B. A., Arnér, E. S. J., & Laín, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4108 · Cited by 37
Camps-Fajol, C., Cavero, D., Minguillón, J., & Surrallés, J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107544 · Cited by 36
Dickinson, E. R., Jurneczko, E., Nicholson, J., Hupp, T. R., Zawacka‐Pankau, J., Selivanova, G., & Barran, P. E. (2015) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2015.00039 · Cited by 36
Zhu, H.-P., Xie, K., He, X., Huang, W., Zeng, R., Yang, F., Peng, C. Y., He, G., & Han, B. (2019) · Chemical Communications · doi:10.1039/c9cc05916d · Cited by 36
Helix mimetics: Recent developments
Wilson, A. J. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.05.001 · Cited by 37
PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
Han, X., Wei, W., & Sun, Y. (2022) · Acta Materia Medica · doi:10.15212/amm-2022-0010 · Cited by 35
Holenz, J., & Stoy, P. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.001 · Cited by 35
Balasubramanian, K., & Gupta, S. P. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304152704 · Cited by 36
Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors
Grigoreva, T. A., Novikova, D., Petukhov, A., Gureev, M., Garabadzhiu, A. V., Melino, G., Barlev, N. A., & Tribulovich, V. G. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.049 · Cited by 35
Small Molecule Modulators of RING-Type E3 Ligases: MDM and Cullin Families as Targets
Bulatov, E., Zagidullin, A. A., Valiullina, A., Sayarova, R., & Rizvanov, A. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00450 · Cited by 35
Therapeutic Strategies to Activate p53
Aguilar, A., & Wang, S. (2022) · Pharmaceuticals · doi:10.3390/ph16010024 · Cited by 34
Evaluating Cellular Drug Uptake with Fluorescent Sensor Proteins
Scarabelli, S., Tan, K., Griss, R., Hovius, R., D’Alessandro, P. L., Vorherr, T. E., & Johnsson, K. (2017) · ACS Sensors · doi:10.1021/acssensors.7b00331 · Cited by 33
Bulatov, E., Valiullina, A., Sayarova, R., & Rizvanov, A. A. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.08.001 · Cited by 33
Zanjirband, M., & Rahgozar, S. (2019) · Current Drug Targets · doi:10.2174/1389450120666190402120701 · Cited by 32
Azme, E., Hasan, M. M., Ali, M. L., Alam, R., Hoque, N., Noushin, F., Kabir, M. F., Islam, M. A., Nipun, T. S., Hossen, S. M. M., et al. (2025) · Frontiers in Chemistry · doi:10.3389/fchem.2025.1527008 · Cited by 31
Discovery of MK-4688 : an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction
Reutershan, M. H., Machacek, M. R., Altman, M. D., Bogen, S. L., Cai, M., Cammarano, C., Chen, D., Christopher, M., Cryan, J. G., Daublain, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01524 · Cited by 31
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy
Li, H., Cai, X., Yang, X., & Zhang, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116506 · Cited by 31
Xue, X., Wei, J., Xu, L., Xi, M., Xu, X., Liu, F., Guo, X., Wang, L., Zhang, X., Zhang, M., et al. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400348f · Cited by 31
Recent Synthetic Approaches towards Small Molecule Reactivators of p53
Silva, J. L., Lima, C. G. S., Rangel, L. P., Ferretti, G. D. S., Pauli, F. P., Ribeiro, R. C. B., Silva, T. B., da Silva, F. D. C., & Ferreira, V. F. (2020) · Biomolecules · doi:10.3390/biom10040635 · Cited by 31
Resistance acquisition to MDM2 inhibitors
Cinatl, J., Speidel, D., Hardcastle, I., & Michaelis, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140035 · Cited by 30
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
“Similar to nutlin-3a, the nutilin derivative RG7112 (RO5045337) is a nongenotoxic inhibitor that blocks the p53–MDM2 interaction by binding to the p53 pocket on MDM2 [56,61].”
BackgroundAnticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2
Anifowose, A., Agbowuro, A. A., Yang, X., & Wang, B. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02574-9 · Cited by 30
Blackburn, T. J., Ahmed, S. U., Coxon, C. R., Liu, J., Lü, X., Golding, B. T., Griffin, R. J., Hutton, C., Newell, D. R., Ojo, O. S., et al. (2013) · MedChemComm · doi:10.1039/c3md00161j · Cited by 30
Self-citationDiscovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2–p53 Interaction
Yu, M., Wang, Y., Zhu, J., Bartberger, M. D., Canon, J. R., Chen, A., Chow, D. T., Eksterowicz, J. E., Fox, B. M., Fu, J., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500142b · Cited by 30
Self-citationCiardullo, C., Aptullahoğlu, E., Woodhouse, L. C., Lin, W., Wallis, J. P., Marr, H. J., Marshall, S. R., Bown, N. P., Willmore, E., & Lunec, J. (2019) · Haematologica · doi:10.3324/haematol.2018.206631 · Cited by 30
MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)
Rusiecki, R., Witkowski, J., & Jaszczewska‐Adamczak, J. A. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666191022163540 · Cited by 30
Hoffman-Luca, C. G., Yang, C.-Y., Lu, J., Ziazadeh, D., McEachern, D., Debussche, L., & Wang, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128807 · Cited by 28
Structure and function of MDM2 and MDM4 in health and disease
Zhu, I. Y., Lloyd, A., Critchley, W. R., Saikia, Q., Jade, D., Divan, A., Zeqiraj, E., Harrison, M. A., Brown, C. J., & Ponnambalam, S. (2025) · Biochemical Journal · doi:10.1042/bcj20240757 · Cited by 29
Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer
Huang, F., Li, K., Shevach, J. W., & Wang, Q. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.04.004 · Cited by 29
Transcription Factors and Cancer: Approaches to Targeting
Shiah, J. V., Johnson, D. E., & Grandis, J. R. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000639 · Cited by 29
Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
Olaoba, O. T., Adelusi, T. I., Yang, M. J., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16101808 · Cited by 29
Nietzold, F., Rubner, S., & Berg, T. (2019) · Chemical Communications · doi:10.1039/c9cc07795b · Cited by 29
Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction
Huang, Y., Wang, L., Zhou, Y., Bai, J., Li, N., Su, Z., & Cheng, X. (2025) · Cells · doi:10.3390/cells14080583 · Cited by 27
Transcription Factors and Methods for the Pharmacological Correction of Their Activity
Guryanova, S. V., Maksimova, T. V., & Мухамедовна, А. М. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136394 · Cited by 27
p53: An Attractive Therapeutic Target for Cancer
Patel, K. R., & Patel, H. D. (2019) · Current Medicinal Chemistry · doi:10.2174/1573406415666190621094704 · Cited by 27
Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest in cancer
Zarneshan, S. N., Fakhri, S., Bachtel, G., & Bishayee, A. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.007 · Cited by 27
Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents
Zhang, L., Ren, W. T., Wang, X., Zhang, J., Liu, J., Zhao, L., & Zhang, X. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.021 · Cited by 27
Self-citationPunganuru, S. R., Arutla, V., Zhao, W., Rajaei, M., Deokar, H. S., Zhang, R., Buolamwini, J. K., Srivenugopal, K. S., & Wang, W. (2020) · Cells · doi:10.3390/cells9071592 · Cited by 27
Selective and Potent Proteomimetic Inhibitors of Intracellular Protein–Protein Interactions
Barnard, A., Long, K., Martin, H. L., Miles, J. A., Edwards, T. A., Tomlinson, D. C., Macdonald, A., & Wilson, A. J. (2015) · Angewandte Chemie · doi:10.1002/ange.201410810 · Cited by 27
Targeting p53 in chronic lymphocytic leukemia
Moia, R., Boggione, P., Mahmoud, A. M., Kodipad, A. A., Adhinaveni, R., Sagiraju, S., Patriarca, A., & Gaïdano, G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1832465 · Cited by 27
Zhou, M., Lin, Y., Chen, X., Xu, G., Chung, L. W., & Tang, W. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300334 · Cited by 26
Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds
Liu, L., He, B., Miles, J. A., Wang, W., Mao, Z., Che, W. I., Lu, J., Chen, X., Wilson, A. J., Ma, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7369 · Cited by 26
Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases
Blaquière, N., Villemure, E., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01451 · Cited by 26
Pi, L., Rooprai, J., Allan, D., Atkins, H., Bredeson, C., Fulcher, A., Ito, C., Ramsay, T., Shorr, Stanford, W., et al. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.106222 · Cited by 25
Yu, Z., Zhuang, C., Wu, Y., Guo, Z., Li, J., Dong, G., Yao, J., Sheng, C., Miao, Z., & Zhang, W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150915741 · Cited by 25
Rimmler, G., Alker, A., Bosco, M., Diodone, R., Fishlock, D., Hildbrand, S., Kuhn, B., Moessner, C., Peters, C., Rege, P. D., et al. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00319 · Cited by 25
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., & Salaroli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073887 · Cited by 24
E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential
Liu, Y., Duan, C., & Zhang, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.645864 · Cited by 24
Jiang, Y., Ni, S., Xiao, B., & Jia, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.019 · Cited by 23
Bazanov, D. R., Pervushin, N. V., Savin, E. V., Tsymliakov, M. D., Maksutova, A. I., Savitskaya, V. Y., Sosonyuk, S. E., Gracheva, Y. A., Seliverstov, M. Y., Lozinskaya, N. A., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15040444 · Cited by 22
Cheng, J., Yan, Z., Jiang, K., Liu, C., Xu, D., Lyu, X., Hu, X., Zhang, S., Zhou, Y., Li, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01815 · Cited by 22
Harnessing p53 for targeted cancer therapy: new advances and future directions
Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 22
Houston, D. R., Yen, L.-H., Pettit, S. B., & Walkinshaw, M. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121424 · Cited by 22
Absolute Binding Free Energy Calculations for Highly Flexible Protein MDM2 and Its Inhibitors
Singh, N., & Li, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134765 · Cited by 22
Sinha, A., Zou, Y., Patel, A. S., Yoo, S., Jiang, F., Sato, T., Kong, R., Watanabe, H., Zhu, J., Massion, P. P., et al. (2022) · Cancers · doi:10.3390/cancers14030708 · Cited by 22
Targeting cellular senescence to combat cancer and ageing
Wang, C., Hao, X., & Zhang, R. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13266 · Cited by 21
Shu, L., Gu, C., Fishlock, D., & Li, Z. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00320 · Cited by 21
Reactivation of p53 via MDM2 inhibition
Kim, E. S., & Shohet, J. M. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.302 · Cited by 21
Liu, Y., Zhang, X., Chen, X., & Zhang, F. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2025.123621 · Cited by 20
TPI1 promotes p53 ubiquitination in bladder cancer by recruiting AKT to enhance MDM2 phosphorylation
Wang, C., Wan, S., Li, K., Chen, S., Shu, Y., Liu, S., & Yang, L. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107695 · Cited by 196
Bhatia, N., Khator, R., Kulkarni, S., Singh, Y., Kumar, P., & Thareja, S. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221114103924 · Cited by 20
Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity
Ivanenkov, Y. A., Kukushkin, M. E., Beloglazkina, A. A., Shafikov, R. R., Barashkin, A. A., Ayginin, A. A., Serebryakova, M. S., Majouga, A. G., Skvortsov, D. A., Тафеенко, В. А., et al. (2023) · Molecules · doi:10.3390/molecules28031325 · Cited by 20
Neochoritis, C. G., Estrada‐Ortiz, N., Khoury, K., & Dömling, A. S. S. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00012-2 · Cited by 20
Patil, S. A., Addo, J. K., Deokar, H. S., Sun, S., Wang, J., Li, W., Suttle, D. P., Wang, W., Zhang, R., & Buolamwini, J. K. (2017) · Drug Designing Open Access · doi:10.4172/2169-0138.1000143 · Cited by 20
Yao, J., Liang, X., Xu, S., Liu, Y., Shui, L., Li, S., Guo, H., Xiao, Z., Zhao, Y., & Zheng, M. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.11.035 · Cited by 19
Small-Molecule Inhibitors of Protein–Protein Interactions
Liu, Z., Chen, H., Wold, E. A., & Zhou, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12326-1 · Cited by 19
Bazanov, D. R., Pervushin, N. V., Savin, E. V., Tsymliakov, M. D., Maksutova, A. I., Sosonyuk, S. E., Kopeina, G. S., & Lozinskaya, N. A. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02802-w · Cited by 18
Aguilar, A., Yang, J., Li, Y., McEachern, D., Huang, L., Razzouk, S., & Wang, S. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01818 · Cited by 18
Small-molecule modulation of p53 protein-protein interactions
Kuusk, A., Boyd, H., Chen, H., & Ottmann, C. (2020) · Biological Chemistry · doi:10.1515/hsz-2019-0405 · Cited by 18
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 18
Activity‐Directed Synthesis of Inhibitors of the p53/ h DM2 Protein–Protein Interaction
Green, A. I., Hóbor, F., Tinworth, C. P., Warriner, S. L., Wilson, A. J., & Nelson, A. S. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002153 · Cited by 18
An update patent review of MDM2–p53 interaction inhibitors (2019–2023)
Twarda‐Clapa, A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2419836 · Cited by 17
Key genes altered in glioblastoma based on bioinformatics (Review)
Ghafari, M. A., Jaafari, N. E., Mouallem, M., Maassarani, T., El‐Sibai, M., & Abi‐Habib, R. J. (2025) · Oncology Letters · doi:10.3892/ol.2025.14989 · Cited by 17
Metadata
- Authors
- Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., Tovar, C., Packman, K., Vassilev, L., & Graves, B.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Discovery Chemistry, ‡Discovery Oncology, §Discovery Technologies, ∥Non-Clinical Development, Roche Research Center, Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
- Corresponding author
- Vu, Binh
- ORCID
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-04-04
- Volume
- 4
- Issue
- 5
- Pages
- 466-469
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4027145
- OpenAlex
- W1985567682
- Cited by
- 395
- References
- 24
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 28 · 2023: 39 · 2022: 39 · 2021: 36 · 2020: 39 · 2019: 39 · 2018: 19 · 2017: 19 · 2016: 16 · 2015: 28 · 2014: 20 · 2013: 8
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- RG7112, MDM2 inhibitors, p53, p53-MDM2 interaction, small molecule drug discovery, p53 stabilization, cancer therapy, cell cycle arrest, apoptosis, tumor xenografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.